التفاصيل البيبلوغرافية
| العنوان: |
Phase 1/2 study of epacadostat in combination with durvalumab in patients with metastatic solid tumors. |
| المؤلفون: |
Naing, Aung, Algazi, Alain P., Falchook, Gerald S., Creelan, Benjamin C., Powderly, John, Rosen, Seth, Barve, Minal, Mettu, Niharika B., Triozzi, Pierre L., Hamm, John, Zhou, Gongfu, Walker, Chris, Dong, Zhiwan, Patel, Manish R. |
| المصدر: |
Cancer (0008543X); Jan2023, Vol. 129 Issue 1, p71-81, 11p |
| مصطلحات موضوعية: |
INDOLEAMINE 2,3-dioxygenase, IMMUNE checkpoint inhibitors, ADVERSE health care events, KYNURENINE, PHARMACODYNAMICS |
| مستخلص: |
BACKGROUND: Targeting programmed cell death protein 1 (PD‐1) and indoleamine 2,3‐dioxygenase (IDO1) pathways is an appealing option for cancer treatment. METHODS: The open‐label, phase 1/2 ECHO‐203 study evaluated the safety, tolerability, and efficacy of the IDO1 inhibitor epacadostat in combination with durvalumab, a human anti–PD‐L1 monoclonal antibody in adult patients with advanced solid tumors. RESULTS: The most common treatment‐related adverse events were fatigue (30.7%), nausea (21.0%), decreased appetite (13.1%), pruritus (12.5%), maculopapular rash (10.8%), and diarrhea (10.2%). Objective response rate (ORR) in the overall phase 2 population was 12.0%. Higher ORR was observed in immune checkpoint inhibitor (CPI)‐naïve patients (16.1%) compared with patients who had received previous CPI (4.1%). Epacadostat pharmacodynamics were evaluated by comparing baseline kynurenine levels with those on therapy at various time points. Only the 300‐mg epacadostat dose showed evidence of kynurenine modulation, albeit unsustained. CONCLUSIONS: Epacadostat plus durvalumab was generally well tolerated in patients with advanced solid tumors. ORR was low, and evaluation of kynurenine concentration from baseline to cycle 2, day 1, and cycle 5, day 1, suggested >300 mg epacadostat twice daily is needed to ensure sufficient drug effect. Clinical trial information: A study of epacadostat (INCB024360) in combination with durvalumab (MEDI4736) in subjects with selected advanced solid tumors (ECHO‐203) (NCT02318277). Epacadostat plus durvalumab was generally well tolerated in patients with advanced solid tumors. Objective response rate was low, and evaluation of kynurenine concentration from baseline to cycle 2, day 1, and cycle 5, day 1, suggested that >300 mg twice daily of epacadostat is needed to ensure sufficient drug effect. [ABSTRACT FROM AUTHOR] |
|
Copyright of Cancer (0008543X) is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
Full Text Finder